Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07095465 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Enrolling by Invitation → Recruiting
    • Study sites: 30 to 32
    • Eligibility criteria expanded, about 22 words
  2. Trial sites expanded: 15 → 30 locationsv8
  3. Trial sites expanded: 12 → 15 locations
    • Study description expanded, about 3 words
    v7
  4. Study sites: 11 to 12v6
  5. Study sites: 10 to 11v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 6 to 10v4
  2. Study sites: 4 to 6
    • Start date changed from estimate of Dec 2025 to Nov 14, 2025
    v3
  3. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date: Aug 2025 to Dec 2025
    • Study sites: 0 to 4
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
Trial Details
NCT Number NCT07095465
Lead Sponsor ACADIA Pharmaceuticals Inc.
Conditions
(from sponsor)		 Lewy Body Dementia Psychosis
Enrollment 126 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov